Avicanna (TSX:AVCN) FCF Margin % : 1.15% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avicanna's Free Cash Flow for the three months ended in Mar. 2024 was C$0.07 Mil. Avicanna's Revenue for the three months ended in Mar. 2024 was C$6.45 Mil. Therefore, Avicanna's FCF Margin % for the quarter that ended in Mar. 2024 was 1.15%.

As of today, Avicanna's current FCF Yield % is 0.78%.

The historical rank and industry rank for Avicanna's FCF Margin % or its related term are showing as below:

TSX:AVCN' s FCF Margin % Range Over the Past 10 Years
Min: -15790.48 Med: -997.45 Max: 0.82
Current: 0.82

During the past 8 years, the highest FCF Margin % of Avicanna was 0.82%. The lowest was -15790.48%. And the median was -997.45%.

TSX:AVCN's FCF Margin % is ranked better than
50.93% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs TSX:AVCN: 0.82

Avicanna FCF Margin % Historical Data

The historical data trend for Avicanna's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna FCF Margin % Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-15,790.48

-997.45

-380.91

-185.33

-11.68

Avicanna Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-176.75	-43.11	38.93	-14.84	1.15

Competitive Comparison of Avicanna's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Avicanna's FCF Margin % falls into.

Avicanna FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Avicanna's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.962	/	16.791
	=	-11.68 %

Avicanna's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0.074	/	6.446
	=	1.15 %

Avicanna FCF Margin % Related Terms

Thank you for viewing the detailed overview of Avicanna's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna (TSX:AVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash

10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines